SSRIs, SNRIs, and Pregnancy: Reassuring Data on Neurodevelopmental Outcomes
A large meta-analysis finds no causal link between prenatal antidepressant exposure and neurodevelopmental disorders after accounting for confounding factors.
Fact Sheet: Valproic Acid (Depakote) and Pregnancy
Using valproic acid (Depakote) during pregnancy raises important safety concerns, including increased risks of congenital malformations and neurodevelopmental disorders.
Isn’t It Time for Stricter Valproic Acid Warnings for Women of Reproductive Age?
Despite FDA warnings, valproate is still prescribed to women of reproductive age, placing children at risk for birth defects and neurodevelopmental disorders.
Essential Reads: Prenatal Exposure to Valproate and Risk of Neurodevelopmental Disorders in Offspring
Prenatal exposure to valproate is linked to increased risk of autism spectrum disorder, ADHD, lower IQ, and intellectual disability, especially at higher doses.
Prenatal Valproic Acid (Depakote) Exposure Increases Risk for Neurodevelopmental Disorders
While we have considerable information regarding the teratogenic risk associated with prenatal exposure to various antiepileptic drugs (AEDs), we have considerably less information on the impact of exposure to AEDs on behavioral outcomes in [...]
Exposure to Valproic Acid and Increased Risk of Autism Spectrum Disorders
There have long been concerns regarding the use of the anticonvulsant valproate (Depakote, VPA) during pregnancy. First trimester use of valproate has been associated with a 3-5% risk of neural tube defects, as well as an increased risk of other malformations affecting the heart and other organ systems. Multiple reports have also indicated that in utero exposure to valproate may also negatively affect cognitive development.